Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SBB in connection with an issue of D shares and mandatory convertibles
Mandate

Vinge advises SBB in connection with an issue of D shares and mandatory convertibles

July 29, 2020 Banking and Finance Corporate Tax Capital Markets and Public M&A

The board of directors of Samhällsbyggnadsbolaget i Norden has, on the basis of an authorization granted by the annual general meeting, resolved on a directed issue of class D shares and a directed issue of subordinated convertibles mandatorily convertible into class B shares, whereby the company raises proceeds of SEK 3.4 billion before issue costs.

SBB is a major Nordic social infrastructure property company with a property portfolio with a market value of SEK 73 billion as of 30 June 2020. SBB’s Class B and Class D common shares are listed on Nasdaq Stockholm, Large Cap.

Vinge’s team consisted of Jesper Schönbeck, Malte St Cyr Ohm, Julia Hirschberg and Amanda M Johansson (Capital Market and Public M&A), Maria Schultzberg (Tax) and Albert Wållgren (Banking and Finance).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025